Please wait while we load the requested 8-K report or click the link below:
For Further Information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA 93534-7059
|Simulations Plus Investor Relations||Hayden IR|
|Ms. Renee Bouche||Mr. Cameron Donahue|
For Immediate Release:
January 11, 2021
Simulations Plus Reports Record First Quarter FY2021 Financial Results
First quarter revenue of $10.7 million, reflecting 14% year-over-year growth
Board of Directors announces quarterly dividend of $0.06 per share
LANCASTER, CA,January 11, 2021 – Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2021.
Financial highlights compared with the corresponding period last fiscal year:
|·||Revenue increased 14% to $10.7 million|
|·||Gross profit increased 22% to $8.3 million|
|·||Gross margin was 77%, up from 72%|
|·||Net income increased 21% to $2.5 million|
|·||Diluted earnings per share increased 9% to $0.12|
Shawn O’Connor, chief executive officer of Simulations Plus, said: “Our first quarter financial results were in line with our expectations highlighted by strong, double-digit revenue growth and increased profitability, despite a challenging comparison to the first quarter of fiscal 2020 that benefited from unusually strong results in our DILIsym division. The strategic investments in our sales and marketing infrastructure, and a growing reliance on modeling and simulation in the drug development ecosystem continue to facilitate strong revenue growth, as Simulations Plus bolsters its already strong position in the marketplace. The acquisition of Lixoft has meaningfully expanded our addressable market. In addition, this acquisition has had the desired impact of increasing the mix of software revenue, helping expand our overall profitability.”
“We recently signed a large COVID-19-related consulting services project with a large pharmaceutical client, validating the resources we devoted to our COVID-19 initiative and demonstrating the increasing value we play in support of our clients,” added Mr. O’Connor. “We also signed a new three-year project with a large private foundation as well as three new projects with a large non-profit biotechnology institute. Looking ahead, demand for our consulting services remains strong and next generation releases of several of our software products that are scheduled for fiscal 2021 reinforce our confidence in delivering another year of organic growth of 15% to 20% in fiscal 2021.”
Quarterly Dividend Declared
The Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock payable on February 1, 2021, to shareholders of record as of January 25, 2021. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.
Investor Conference Call
The Company has announced an investor conference call that will be webcast live at 1:15 p.m. PST/4:15 p.m. EST on Monday, January 11, 2021. The live webcast/teleconference will be accessible by here or by calling 1-201-389-0879. Please join 5 to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of our new software products as well as improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn | YouTube
--Tables follow --
SIMULATIONS PLUS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
|(in thousands, except share and per share amounts)||November 30,||August 31,|
|Cash and cash equivalents||$||27,651||$||49,207|
|Accounts receivable, net of allowance for doubtful accounts of $50 and $50||7,331||7,422|
|Revenues in excess of billings||2,837||3,093|
|Prepaid income taxes||560||970|
|Prepaid expenses and other current assets||1,738||1,596|
|Total current assets||131,232||129,092|
|Capitalized computer software development costs,|
|net of accumulated amortization of $13,906 and $13,582||6,490||6,087|
|Property and equipment, net||596||438|
|Operating lease right of use assets||768||927|
|Intellectual property, net of accumulated amortization of $5,444 and $5,087||11,541||11,898|
|Other intangible assets, net of accumulated amortization of $1,779 and $1,642||6,871||7,008|
|LIABILITIES AND SHAREHOLDERS' EQUITY|
|Accrued payroll and other expenses||2,300||2,251|
|Current portion - contracts payable||2,000||2,000|
|Billings in excess of revenues||206||141|
|Operating lease liability, current portion||395||463|
|Total current liabilities||5,477||5,506|
|Deferred income taxes, net||2,401||2,354|
|Operating lease liability||376||463|
|Payments due under contracts payable||4,185||4,064|
|Commitments and contingencies|
|Preferred stock, $0.001 par value 10,000,000 shares authorized, no shares issued and outstanding||–||–|
|Common stock, $0.001 par value and additional paid in capital — 50,000,000 shares authorized, 19,958,760 and 19,923,277 shares issued and outstanding||129,253||128,541|
|Accumulated other comprehensive income||58||58|
|Total shareholders' equity||158,031||156,035|
|Total liabilities and shareholders' equity||$||170,470||$||168,422|
SIMULATIONS PLUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
For the three months ended November 30,
|(in thousands, except per common share amounts)||2020||2019|
|Cost of revenues||2,433||2,643|
|Selling, general, and administrative||4,408||3,514|
|Research and development||809||526|
|Total operating expenses||5,217||4,040|
|Income from operations||3,051||2,718|
|Other income (expense)|
|Change in value of contingent consideration||(121||)||–|
|Income on currency exchange||5||4|
|Total other income (expense)||(55||)||15|
|Income before provision for income taxes||2,996||2,733|
|Provision for income taxes||(517||)||(675||)|
|Earnings per share|
|Weighted-average common shares outstanding|
View differences made from one to another to evaluate Simulations Plus Inc's financial trajectory
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were
removed , and by Simulations Plus Inc.